AU2018253088B2 - Method for producing recombinant virus - Google Patents

Method for producing recombinant virus Download PDF

Info

Publication number
AU2018253088B2
AU2018253088B2 AU2018253088A AU2018253088A AU2018253088B2 AU 2018253088 B2 AU2018253088 B2 AU 2018253088B2 AU 2018253088 A AU2018253088 A AU 2018253088A AU 2018253088 A AU2018253088 A AU 2018253088A AU 2018253088 B2 AU2018253088 B2 AU 2018253088B2
Authority
AU
Australia
Prior art keywords
leu
pro
gly
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018253088A
Other languages
English (en)
Other versions
AU2018253088A1 (en
Inventor
Christopher Larson
Bryan T. Oronsky
Tony R. REID
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epicentrx Inc
Original Assignee
Epicentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epicentrx Inc filed Critical Epicentrx Inc
Publication of AU2018253088A1 publication Critical patent/AU2018253088A1/en
Application granted granted Critical
Publication of AU2018253088B2 publication Critical patent/AU2018253088B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018253088A 2017-04-10 2018-04-10 Method for producing recombinant virus Active AU2018253088B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483837P 2017-04-10 2017-04-10
US62/483,837 2017-04-10
PCT/US2018/026977 WO2018191313A1 (en) 2017-04-10 2018-04-10 Method for producing recombinant virus

Publications (2)

Publication Number Publication Date
AU2018253088A1 AU2018253088A1 (en) 2019-11-28
AU2018253088B2 true AU2018253088B2 (en) 2024-09-19

Family

ID=63792776

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018253088A Active AU2018253088B2 (en) 2017-04-10 2018-04-10 Method for producing recombinant virus

Country Status (8)

Country Link
US (2) US11999973B2 (enExample)
EP (1) EP3610003A4 (enExample)
JP (2) JP7229173B2 (enExample)
KR (2) KR20240032169A (enExample)
CN (1) CN111133102B (enExample)
AU (1) AU2018253088B2 (enExample)
CA (1) CA3059605A1 (enExample)
WO (1) WO2018191313A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
CN111793595A (zh) * 2020-07-23 2020-10-20 上海奥浦迈生物科技有限公司 一种hek293细胞无血清培养基
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2003039459A2 (en) 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
US20050153419A1 (en) 2003-12-23 2005-07-14 Schering Corporation Methods for producing cell lines stable in serum-free medium suspension culture
JP4301558B2 (ja) * 2003-12-26 2009-07-22 日東電工株式会社 偏光板用接着剤、偏光板、その製造方法、光学フィルムおよび画像表示装置
PT2403951E (pt) * 2009-03-02 2016-01-29 Univ California Mutantes de adenovírus e1a e e1b de tumores
US20190352669A1 (en) * 2017-01-30 2019-11-21 Epicentrx, Inc. Tumor selective tata-box and caat-box mutants
EP3610003A4 (en) * 2017-04-10 2021-01-06 EpicentRx, Inc. RECOMBINANT VIRUS PRODUCTION PROCESS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RÉNALD GILBERT ET AL: "Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture". *

Also Published As

Publication number Publication date
CN111133102B (zh) 2024-08-16
US12291726B2 (en) 2025-05-06
WO2018191313A1 (en) 2018-10-18
KR20200004313A (ko) 2020-01-13
JP2023053298A (ja) 2023-04-12
US20240294883A1 (en) 2024-09-05
JP2020516277A (ja) 2020-06-11
JP7229173B2 (ja) 2023-02-27
EP3610003A4 (en) 2021-01-06
US20200032223A1 (en) 2020-01-30
EP3610003A1 (en) 2020-02-19
KR20240032169A (ko) 2024-03-08
AU2018253088A1 (en) 2019-11-28
CN111133102A (zh) 2020-05-08
KR102643016B1 (ko) 2024-02-29
US11999973B2 (en) 2024-06-04
CA3059605A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
AU2018253088B2 (en) Method for producing recombinant virus
US12280123B2 (en) Recombinant adenoviruses carrying transgenes
US12036247B2 (en) Multiple transgene recombinant adenovirus
EP3573632B1 (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
US20190352616A1 (en) Multiple transgene recombinant adenovirus
JP2019500909A (ja) 腫瘍溶解性ウイルス株
WO2018204677A1 (en) Oncolytic adenovirus formulation
US20250388930A1 (en) Tumor selective tata-box and caat-box mutants
HK40018033A (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
HK40018033B (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
TW202342758A (zh) 轉錄及轉譯雙重調節之溶瘤單純疱疹病毒載體

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)